ATOSSA THERAPEUTICS, INC.
ATOS · Nasdaq · United States
Share price · ATOS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ATOS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026-9.0%
Nothing announced by ATOS that day or the session before.
- 19 Oct 2026-12.0%
- 16 Oct 2026+9.8%
Nothing announced by ATOS that day or the session before.
- 13 Oct 2026+7.2%
Nothing announced by ATOS that day or the session before.
- 1 Oct 2026+16.4%
Nothing announced by ATOS that day or the session before.
- 11 Jun 2026-41.1%
- 11 Feb 2026-16.0%
- 2 Feb 2026-34.6%
Nothing announced by ATOS that day or the session before.
- 16 Jan 2026+6.9%
- 14 Jan 2026-6.3%
Nothing announced by ATOS that day or the session before.
Share of unusual movement by asset
For each asset, the share of ATOS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
(Z)-endoxifenevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 3% |
| Other company news (earnings, financing, releases naming no asset) | — | 36% |
| Sessions with no dated event | — | 61% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Estrogen receptor (antagonist)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $3.4M | $21M | $5.6M-$5.5M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $4.9M | $26M | $8.5M-$9.6M operating cash flow | report ↗ |
| 2026-Q1 | — | $4.8M | $32M | $9.6M-$9.6M operating cash flow | report ↗ |
| 2025-Q3 | — | $5.4M | $52M | $8.7M-$6.0M operating cash flow | report ↗ |
| 2025-Q2 | — | $5.5M | $58M | $8.4M-$7.3M operating cash flow | report ↗ |
| 2025-Q1 | — | $4.2M | $65M | $6.7M-$6.0M operating cash flow | report ↗ |
| 2024-Q3 | — | $3.4M | $75M | $7.2M-$4.8M operating cash flow | report ↗ |
| 2024-Q2 | — | $3.5M | $80M | $6.0M-$4.5M operating cash flow | report ↗ |
| 2024-Q1 | — | $3.8M | $84M | $5.9M-$4.7M operating cash flow | report ↗ |
| 2023-Q3 | — | $4.5M | $94M | $6.2M-$3.9M operating cash flow | report ↗ |
| 2023-Q2 | — | $3.7M | $99M | $9.8M-$4.5M operating cash flow | report ↗ |
| 2023-Q1 | — | $3.5M | $104M | $6.3M-$7.0M operating cash flow | report ↗ |
| 2022-Q3 | — | $5.2M | $117M | $8.0M-$5.4M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.4M | $126M | $6.7M-$6.0M operating cash flow | report ↗ |
| 2022-Q1 | — | $1.5M | $131M | $4.8M-$4.9M operating cash flow | report ↗ |
| 2021-Q3 | — | $2.2M | $140M | $5.2M-$3.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $21M | $41M | $8.7M-$30M operating cash flow | report ↗ |
Atossa Therapeutics reported no revenue for fiscal 2025. R&D expenses were $21.19M, up 50.1% YoY from $14.12M, while cash and equivalents were $41.3M. The company recorded a net loss of $34.77M and a reported quarterly net burn of $34.77M.
The clinical-stage biopharma company is advancing oral (Z)-endoxifen across multiple Phase 2 trials, including Karisma, I-SPY 2, RECAST DCIS, and EVANGELINE. During the period, the FDA granted (Z)-endoxifen Rare Pediatric Disease and Orphan Drug designations for Duchenne muscular dystrophy. Management expects existing resources to fund operations for the next 12 months; the company also effected a 1-for-15 reverse stock split in February 2026 to regain Nasdaq compliance and entered into an at-the-market offering agreement for up to $50M.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-05-12 | Cigler Tessa · director | Award / grant | 10,000 | — | — | Form 4 |
| 2026-05-12 | Galli Stephen J · director | Award / grant | 10,000 | — | — | Form 4 |
| 2026-05-12 | Finn Jonathan · director | Award / grant | 10,000 | — | — | Form 4 |
| 2026-05-12 | Remmel H. Lawrence · director | Award / grant | 10,000 | — | — | Form 4 |
| 2026-05-12 | Chen Shu-Chih · director | Award / grant | 10,000 | — | — | Form 4 |
| 2026-05-12 | Steinhart Richard I · director | Award / grant | 10,000 | — | — | Form 4 |
| 2026-03-27 | QUAY STEVEN C · director, President & CEO | Award / grant | 65,000 | — | — | Form 4 |
| 2026-03-26 | Daniel Mark James · Chief Financial Officer | Award / grant | 63,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 31 reporting institutions held 1.2M shares ($6.5M, 12.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 349,096 | $1.8M |
| 2 | AMERIPRISE FINANCIAL INC | 255,134 | $1.3M |
| 3 | BlackRock, Inc. | 133,169 | $700K |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 109,007 | $573K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 97,061 | $511K |
| 6 | UBS Group AG | 92,034 | $484K |
| 7 | MILLENNIUM MANAGEMENT LLC | 66,739 | $351K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 52,235 | $275K |
| 9 | STATE STREET CORP | 39,761 | $209K |
| 10 | NORTHERN TRUST CORP | 19,224 | $101K |
| 11 | MORGAN STANLEY | 16,202 | $85K |
| 12 | Vanguard Global Advisers, LLC | 3,089 | $16K |
| 13 | JONES FINANCIAL COMPANIES LLLP | 2,061 | $10K |
| 14 | Tower Research Capital LLC (TRC) | 863 | $5K |
| 15 | GROUP ONE TRADING LLC | 609 | $3K |